Koszela Kamil, Woldańska-Okońska Marta, Stypińska Barbara, Gasik Robert
Department of Neuroorthopedics and Neurology Clinic and Polyclinic, National Institute of Geriatrics, Rheumatology and Rehabilitation in Warsaw, 02-637 Warsaw, Poland.
Department of Internal Medicine, Rehabilitation and Physical Medicine, Medical University of Lodz, 90-419 Lodz, Poland.
Biomedicines. 2025 Aug 4;13(8):1893. doi: 10.3390/biomedicines13081893.
: Chronic cervical myofascial pain syndrome (CMPS) is often diagnosed in the current population by doctors of various specialties. One method of treating spinal pathology is mesotherapy. The purpose of this study is to evaluate the efficacy and safety of collagen mesotherapy, as well as to assess the frequency of pain medication after mesotherapy in chronic CMPS. : Patients were diagnosed and treated by an orthopedist in three different offices between 1 January 2018 and 31 December 2024. The patients were diagnosed with chronic CMPS. Patients were qualified for cervical spine mesotherapy, which was performed weekly, in five repetitions. Retrospectively, based on medical records and in accordance with inclusion and exclusion criteria, two groups were created: group I ( = 65) with injectable type I collagen and group II ( = 65) with 1% lignocaine. Patients were evaluated using the VAS and Laitinen scale before the start of therapy, 1 week after the end of therapy, and at 3-month follow-up. In addition, the frequency of taking analgesic medications after mesotherapy was assessed. : After mesotherapy of the cervical spine with both injectable collagen type I and lignocaine 1%, statistically significant improvements were observed in terms of a decrease in pain on the scales used ( < 0.001), as well as a decrease in analgesic medication intake ( < 0.001). Collagen treatment yielded better results after 3 months of follow-up. No mesotherapy-related side effects were observed during the treatment or follow-up periods. : Cervical spine mesotherapy using injectable type I collagen and lignocaine 1% is an effective and safe method for chronic CMPS. At a 3-month follow-up, injectable type I collagen appears to be more effective. After mesotherapy and at the 3-month follow-up, both groups reported less pain medication intake compared to before the intervention.
慢性颈肌筋膜疼痛综合征（CMPS）在当前人群中常由各专科医生诊断。治疗脊柱病变的一种方法是中胚层疗法。本研究的目的是评估胶原中胚层疗法的疗效和安全性，并评估慢性CMPS患者中胚层疗法后止痛药物的使用频率。
2018年1月1日至2024年12月31日期间，患者在三个不同的诊所由骨科医生进行诊断和治疗。患者被诊断为慢性CMPS。符合条件的患者接受颈椎中胚层疗法，每周进行一次，共五次。回顾性地，根据病历并按照纳入和排除标准，创建了两组：第一组（n = 65）接受注射用I型胶原蛋白治疗，第二组（n = 65）接受1%利多卡因治疗。在治疗开始前、治疗结束后1周以及3个月随访时，使用视觉模拟评分法（VAS）和莱蒂宁量表对患者进行评估。此外，还评估了中胚层疗法后服用止痛药物的频率。
在用注射用I型胶原蛋白和1%利多卡因进行颈椎中胚层疗法后，在所用量表上疼痛减轻方面观察到统计学上的显著改善（P < 0.001），以及止痛药物摄入量减少（P < 0.001）。随访3个月后，胶原蛋白治疗效果更佳。在治疗期间或随访期间未观察到与中胚层疗法相关的副作用。
使用注射用I型胶原蛋白和1%利多卡因的颈椎中胚层疗法是治疗慢性CMPS的一种有效且安全的方法。在3个月随访时，注射用I型胶原蛋白似乎更有效。与干预前相比，中胚层疗法后及3个月随访时，两组患者的止痛药物摄入量均减少。
